D. Shen

发表

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

R. Levy, M. Czuczman, A. Ho, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy

L. Pukac, N. Avisar, D. Shen, 2015, Cancer Chemotherapy and Pharmacology.

Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphoma.

Antonio J. Grillo-López, P. Multani, C. White, 2001, Current pharmaceutical biotechnology.

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program

M. Czuczman, P. Mclaughlin, F. Cabanillas, 2023, Journal of Clinical Oncology.

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.

M. Czuczman, D. Maloney, J. Rosenberg, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.

C. White, C. Varns, D. Shen, 1999, Seminars in oncology.

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)

J. Burke, R. Patt, R. Lencioni, 2019, Oncoimmunology.

Antibody Therapy with Rituximab for Patients with Low-Grade Non-Hodgkin’s Lymphoma

S. Dowden, C. White, C. Varns, 1999, Oncology Research and Treatment.

Final Results of a Randomized Controlled Study of the Ibritumomab Tiuxetan Radioimmunotherapy Regimen vs a Standard Course of Rituximab Immunotherapy for B-Cell Non-Hodgkin’s Lymphoma

L. Gordon, M. Czuczman, J. Murray, 2001 .

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.

M. Czuczman, D. Maloney, P. Mclaughlin, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)

R. Patt, D. Kirn, J. Limacher, 2019, Oncoimmunology.